Summary: <p>This issue we look at short-term outcomes used to assess multiple sclerosis treatments, and their power to predict long-term disability, with Douglas Goodin (professor of clinical neurology, University of California, San Francisco).</p><p>We return to the association between cerebral amyloid angiopathy and intracerebral haemorrhage, as Neshika Samarasekera (Division of Clinical Neurosciences, University of Edinburgh) talks us through her research examining the link.</p><p>And Angela Vincent (emeritus professor at the Nuffield Department of Clinical Neurosciences, University of Oxford) looks back at the beginning of her career investigating autoantibodies in neurological diseases.</p><p>See also:</p><p>Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis http://tinyurl.com/ab7sdd9</p><p>The association between cerebral amyloid angiopathy and intracerebral haemorrhage: systematic review and meta-analysis http://tinyurl.com/bewdkzf</p><p>Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays http://tinyurl.com/axg6a98</p>
